Table 1 Baseline characteristics.
From: Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
N = 1194 | |
|---|---|
Baseline characteristics | Median (range) or n/N (%) |
Age, y | 66 (29–88) |
Gender | Male: 713 (59.7); Female: 481 (40.3) |
Performance status | ECOG 0-2: 1117 (93.6) |
ECOG > 2: 77 (6.4) | |
Cardiac involvement | 791 (66.2) |
Mayo stage (European modification of Mayo stage) | I: 183 (15.3) |
II: 409 (34.3) | |
IIIa: 418 (35) | |
IIIb: 184 (15.4) | |
NT-proBNP, ng/L | 1393 (4–93602) |
High-sensitivity cardiac troponin T, ng/L | 57 (1–742) |
Left ventricular wall thickness, mm | 13 (8–24) |
Renal involvement | 802 (67.3) |
Serum creatinine, µmol/L | 96 (26–1124) |
Proteinuria, g/24 h | 2.9 (0–36) |
Liver involvement | 139 (11.6) |
Alkaline Phosphatase, U/L | 90 (16–2389) |
GI Involvement | 48 (4) |
Autonomic nervous system involvement | 82 (6.9) |
Peripheral nervous system involvement | 85 (7.1) |
Soft tissue involvement | 187 (15.7) |
Heavy chain isotype | IgG: 386 (32.3) |
IgA: 161 (13.5) | |
IgM: 38 (3.2) | |
IgD: 9 (0.8) | |
LC: 312 (26.1) | |
None: 288 (24.1) | |
Serum monoclonal protein, g/L | 8 (IF-45) |
Light chain isotype | Kappa: 258 (21.6) |
Lambda: 936 (78.4) | |
dFLC, mg/L | 208.5 (20.1–15898) |
